Journal of Clinical Oncology, Vol 18, Issue 1
(January), 2000: 87
© 2000 American Society for Clinical Oncology
Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival
By H. J. Mackay,
D. Cameron,
M. Rahilly,
M. J. Mackean,
J. Paul,
S. B. Kaye,
R. Brown
From the CRC Department of Medical Oncology, Cancer Research Campaign, Beatson Laboratories, Glasgow University; Department Pathology, Stobhill National Health Survey Trust; Beatson Oncology Center, Western Infirmary, Glasgow; and Department Oncology, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; for and on behalf of the Edinburgh Breast Unit.
Address reprint requests to Robert Brown, MD, CRC Beatson Laboratories, Glasgow University, Switchback Rd, Glasgow G61 1BD, United Kingdom; email gpma61{at}udcf.gla.ac.uk
PURPOSE: Loss of function or expression of the mismatch repair protein MLH1 and the tumor suppressor protein p53 have been implicated in acquired resistance to anticancer drugs. We have compared the expression of MLH1 and p53 in tumors from women with clinically node-positive breast cancer before and after primary (neoadjuvant) chemotherapy. Further, we have assessed the value of these markers as predictors of response to therapy by correlation with disease-free survival.
PATIENTS AND METHODS: Immunohistochemistry scores of MLH1 and p53 expression were made on 36 tru-cut prechemotherapy biopsies and 29 paired postchemotherapy tumor samples. The significance of the change in scores and their correlation with disease-free survival were evaluated by the Wilcoxon signed rank sum test and Cox proportional hazards regression analysis, respectively.
RESULTS: Primary chemotherapy results in a significant reduction in the percent of cells expressing MLH1 (P = .010). This change in MLH1 expression after chemotherapy is strongly associated with poor disease-free survival (P = .0025). Expression of p53 was not significantly altered by chemotherapy. Neither MLH1 nor p53 expression before chemotherapy predicted disease-free survival or tumor response to chemotherapy. Low MLH1 expression after chemotherapy was an independent predictor of poor disease-free survival on multivariate Cox analysis when considered with other clinicopathologic prognostic factors.
CONCLUSION: Tumor cells that have reduced MLH1 expression seem to have a survival advantage during combined chemotherapy of locally advanced breast cancers, which supports the hypothesis that loss of MLH1 has a role in drug resistance. MLH1 expression after chemotherapy is an independent predictive factor for poor disease-free survival and may, therefore, define a group of patients with drug-resistant breast cancer.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara
Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer
Jpn. J. Clin. Oncol.,
January 3, 2007;
(2007)
hyl122v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. O'Brien and R. Brown
Signalling cell cycle arrest and cell death through the MMR System
Carcinogenesis,
April 1, 2006;
27(4):
682 - 692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Tinari, R. Lattanzio, C. Natoli, E. Cianchetti, D. Angelucci, E. Ricevuto, C. Ficorella, P. Marchetti, S. Alberti, M. Piantelli, et al.
Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival
Clin. Cancer Res.,
March 1, 2006;
12(5):
1501 - 1506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-S. Hsu, C.-K. Wen, Y.-A. Tang, R.-K. Lin, W.-Y. Li, W.-H. Hsu, and Y.-C. Wang
Promoter Hypermethylation Is the Predominant Mechanism in hMLH1 and hMSH2 Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer
Clin. Cancer Res.,
August 1, 2005;
11(15):
5410 - 5416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine
Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea
Clin. Cancer Res.,
February 15, 2005;
11(4):
1539 - 1544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gifford, J. Paul, P. A. Vasey, S. B. Kaye, and R. Brown
The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients
Clin. Cancer Res.,
July 1, 2004;
10(13):
4420 - 4426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Curtin, L.-Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan-Koch, S. E. Webber, B. W. Durkacz, H. A. Calvert, Z. Hostomsky, et al.
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells
Clin. Cancer Res.,
February 1, 2004;
10(3):
881 - 889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kishi, Y. Doki, M. Yano, T. Yasuda, Y. Fujiwara, S. Takiguchi, S. Kim, I. Higuchi, and M. Monden
Reduced MLH1 Expression after Chemotherapy Is an Indicator for Poor Prognosis in Esophageal Cancers
Clin. Cancer Res.,
October 1, 2003;
9(12):
4368 - 4375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yan, S. E. Berry, A. B. Desai, and T. J. Kinsella
DNA Mismatch Repair (MMR) Mediates 6-Thioguanine Genotoxicity by Introducing Single-strand Breaks to Signal a G2-M Arrest in MMR-proficient RKO Cells
Clin. Cancer Res.,
June 1, 2003;
9(6):
2327 - 2334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pectasides, M. Pectasides, D. Farmakis, N. Bountouroglou, M. Nikolaou, M. Koumpou, N. Mylonakis, and C. Kosmas
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study
Ann. Onc.,
April 1, 2003;
14(4):
537 - 542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Matheson and A. G. Hall
Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia
Carcinogenesis,
January 1, 2003;
24(1):
31 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zelek, P. Cottu, M. Tubiana-Hulin, J.-M. Vannetzel, Ph. Chollet, J.-L. Misset, N. Chouaki, M. Marty, E. Gamelin, S. Culine, et al.
Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients
J. Clin. Oncol.,
May 15, 2002;
20(10):
2551 - 2558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic
Cellular and Molecular Pharmacology of Oxaliplatin
Mol. Cancer Ther.,
January 1, 2002;
1(3):
227 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Karran
Mechanisms of tolerance to DNA damaging therapeutic drugs
Carcinogenesis,
December 1, 2001;
22(12):
1931 - 1937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Sood, R. Holmes, M. J. C. Hendrix, and R. E. Buller
Application of the National Cancer Institute International Criteria for Determination of Microsatellite Instability in Ovarian Cancer
Cancer Res.,
June 1, 2001;
61(11):
4371 - 4374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Strathdee, K. Appleton, M. Illand, D. W. M. Millan, J. Sargent, J. Paul, and R. Brown
Primary Ovarian Carcinomas Display Multiple Methylator Phenotypes Involving Known Tumor Suppressor Genes
Am. J. Pathol.,
March 1, 2001;
158(3):
1121 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Plumb, G. Strathdee, J. Sludden, S. B. Kaye, and R. Brown
Reversal of Drug Resistance in Human Tumor Xenografts by 2'-Deoxy-5-azacytidine-induced Demethylation of the hMLH1 Gene Promoter
Cancer Res.,
November 1, 2000;
60(21):
6039 - 6044.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. E. Berry, T. W. Davis, J. E. Schupp, H.-S. Hwang, Niels de Wind, and T. J. Kinsella
Selective Radiosensitization of Drug-resistant MutS Homologue-2 (MSH2) Mismatch Repair-deficient Cells by Halogenated Thymidine (dThd) Analogues: Msh2 Mediates dThd Analogue DNA Levels and the Differential Cytotoxicity and Cell Cycle Effects of the dThd Analogues and 6-Thioguanine
Cancer Res.,
October 1, 2000;
60(20):
5773 - 5780.
[Abstract]
[Full Text]
|
|
|
|
